MC
BLRX

Menta Capital’s BioLineRX BLRX Stock Holding History

Menta Capital’s Portfolio BLRX Stock Details BLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-127
Closed -$33K – 498
2018
Q4 		$33K Buy
+127
New +$61.1K 0.01% 528
2017
Q1 		– Sell
-172
Closed -$95K – 813
2016
Q4 		$95K Buy
172
+3
+2% +$1.86K 0.01% 831
2016
Q3 		$117K Buy
169
+5
+3% +$2.66K 0.01% 781
2016
Q2 		$79K Sell
164
-1
-0.6% -$560 0.01% 831
2016
Q1 		$101K Buy
165
+17
+11% +$10.7K 0.01% 870
2015
Q4 		$115K Buy
148
+70
+90% +$58.1K 0.01% 813
2015
Q3 		$71K Sell
78
-28
-26% -$29.9K 0.01% 686
2015
Q2 		$170K Sell
106
-21
-17% -$26K 0.03% 604
2015
Q1 		$161K Buy
+127
New +$156K 0.02% 637

Other funds holding BLRX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FI
Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
DG
Delek Group Herzliya, Israel $2.59B AUM 1.24% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Menta Capital's BLRX Position: Q1 2019 in Review

Menta Capital sold out of BioLineRX (BLRX) in Q1 2019, closing a stake of 127 shares — an estimated $33K sold.

Menta Capital first reported a position in BLRX in Q1 2015 and held it in 9 quarters. The position peaked at $170K in Q2 2015. 31 funds tracked by Wall St. Rank hold BLRX as of Q1 2019.

  • Menta Capital reported no remaining BioLineRX position as of Q1 2019 after selling out during the quarter.
  • Menta Capital sold 127 BioLineRX shares in Q1 2019, an estimated $33K.
  • Menta Capital first reported a position in BioLineRX in Q1 2015 and held it in 9 quarters.
  • Menta Capital's BioLineRX position peaked at $170K in Q2 2015.
  • 31 funds tracked by Wall St. Rank held BioLineRX as of Q1 2019.

Based on Menta Capital's 13F filing for Q1 2019, filed 1 May 2019.